Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report
Epidermal growth factor receptor (EGFR) exon 20 insertion is not associated with sensitivity to EGFR tyrosine kinase inhibitors and chemotherapy. Here, we report the case of a 41-year-old man who presented a right lower lobe nodule and mediastinal lymph node enlargement diagnosed as EGFR exon 20 ins...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-01-01
|
Series: | Respiratory Medicine Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213007120304500 |
id |
doaj-e7bc98f35f874ba7aa58b5bc0018757a |
---|---|
record_format |
Article |
spelling |
doaj-e7bc98f35f874ba7aa58b5bc0018757a2020-12-17T04:48:44ZengElsevierRespiratory Medicine Case Reports2213-00712020-01-0131101236Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case reportShun Matsuura0Keisuke Morikawa1Yutaro Ito2Namio Kagoo3Tsutomu Kubota4Koshiro Ichijo5Eisuke Mochizuki6Masahiro Uehara7Masanori Harada8Masaru Tsukui9Naoki Koshimizu10Corresponding author. Division of Respiratory Medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, Fujieda, Shizuoka, 426-8677, Japan.; Division of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, JapanDivision of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, JapanDivision of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, JapanDivision of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, JapanDivision of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, JapanDivision of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, JapanDivision of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, JapanDivision of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, JapanDivision of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, JapanDivision of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, JapanDivision of Respiratory Medicine, Fujieda Municipal General Hospital, Shizuoka, JapanEpidermal growth factor receptor (EGFR) exon 20 insertion is not associated with sensitivity to EGFR tyrosine kinase inhibitors and chemotherapy. Here, we report the case of a 41-year-old man who presented a right lower lobe nodule and mediastinal lymph node enlargement diagnosed as EGFR exon 20 insertion adenocarcinoma with high-expression programmed cell death ligand 1 (PD-L1). He showed stable disease to chemoradiation treatment at the primary tumor site. However, durvalumab treatment has good response. Non-small cell lung cancer with EGFR exon 20 insertion and high PD-L1 expression may be treated with immunotherapy exposure.http://www.sciencedirect.com/science/article/pii/S2213007120304500EGFRExon 20 insertionDurvalumabNon-small-cell lung cancer |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Shun Matsuura Keisuke Morikawa Yutaro Ito Namio Kagoo Tsutomu Kubota Koshiro Ichijo Eisuke Mochizuki Masahiro Uehara Masanori Harada Masaru Tsukui Naoki Koshimizu |
spellingShingle |
Shun Matsuura Keisuke Morikawa Yutaro Ito Namio Kagoo Tsutomu Kubota Koshiro Ichijo Eisuke Mochizuki Masahiro Uehara Masanori Harada Masaru Tsukui Naoki Koshimizu Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report Respiratory Medicine Case Reports EGFR Exon 20 insertion Durvalumab Non-small-cell lung cancer |
author_facet |
Shun Matsuura Keisuke Morikawa Yutaro Ito Namio Kagoo Tsutomu Kubota Koshiro Ichijo Eisuke Mochizuki Masahiro Uehara Masanori Harada Masaru Tsukui Naoki Koshimizu |
author_sort |
Shun Matsuura |
title |
Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report |
title_short |
Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report |
title_full |
Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report |
title_fullStr |
Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report |
title_full_unstemmed |
Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report |
title_sort |
good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: a case report |
publisher |
Elsevier |
series |
Respiratory Medicine Case Reports |
issn |
2213-0071 |
publishDate |
2020-01-01 |
description |
Epidermal growth factor receptor (EGFR) exon 20 insertion is not associated with sensitivity to EGFR tyrosine kinase inhibitors and chemotherapy. Here, we report the case of a 41-year-old man who presented a right lower lobe nodule and mediastinal lymph node enlargement diagnosed as EGFR exon 20 insertion adenocarcinoma with high-expression programmed cell death ligand 1 (PD-L1). He showed stable disease to chemoradiation treatment at the primary tumor site. However, durvalumab treatment has good response. Non-small cell lung cancer with EGFR exon 20 insertion and high PD-L1 expression may be treated with immunotherapy exposure. |
topic |
EGFR Exon 20 insertion Durvalumab Non-small-cell lung cancer |
url |
http://www.sciencedirect.com/science/article/pii/S2213007120304500 |
work_keys_str_mv |
AT shunmatsuura goodresponsewithdurvalumabafterchemoradiotherapyforepidermalgrowthfactorreceptorexon20insertionadenocarcinomaacasereport AT keisukemorikawa goodresponsewithdurvalumabafterchemoradiotherapyforepidermalgrowthfactorreceptorexon20insertionadenocarcinomaacasereport AT yutaroito goodresponsewithdurvalumabafterchemoradiotherapyforepidermalgrowthfactorreceptorexon20insertionadenocarcinomaacasereport AT namiokagoo goodresponsewithdurvalumabafterchemoradiotherapyforepidermalgrowthfactorreceptorexon20insertionadenocarcinomaacasereport AT tsutomukubota goodresponsewithdurvalumabafterchemoradiotherapyforepidermalgrowthfactorreceptorexon20insertionadenocarcinomaacasereport AT koshiroichijo goodresponsewithdurvalumabafterchemoradiotherapyforepidermalgrowthfactorreceptorexon20insertionadenocarcinomaacasereport AT eisukemochizuki goodresponsewithdurvalumabafterchemoradiotherapyforepidermalgrowthfactorreceptorexon20insertionadenocarcinomaacasereport AT masahirouehara goodresponsewithdurvalumabafterchemoradiotherapyforepidermalgrowthfactorreceptorexon20insertionadenocarcinomaacasereport AT masanoriharada goodresponsewithdurvalumabafterchemoradiotherapyforepidermalgrowthfactorreceptorexon20insertionadenocarcinomaacasereport AT masarutsukui goodresponsewithdurvalumabafterchemoradiotherapyforepidermalgrowthfactorreceptorexon20insertionadenocarcinomaacasereport AT naokikoshimizu goodresponsewithdurvalumabafterchemoradiotherapyforepidermalgrowthfactorreceptorexon20insertionadenocarcinomaacasereport |
_version_ |
1724380343865180160 |